Key studies show that six months of Roche's (RHHBY.OB) Herceptin breast-cancer treatment is no...


Key studies show that six months of Roche's (RHHBY.OB) Herceptin breast-cancer treatment is no more effective than one year's worth - setting aside a downside risk of $1.5B in lost revenue if the shorter term had shown an advantage. But extending treatment to two years also doesn't look worthwhile, putting a cap on Roche's ability to squeeze out more from the drug before a 2014 patent expiration. RHHBY.OB +0.8% premarket.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs